Novel Autologous, High Concentrated Fibrin as Advanced Hemostatic Agent for Coronary Surgery
Autologous bio-regenerative fibrin can be safely prepared, with no time consuming, and was demonstrated to be a useful tool to decrease allogeneic blood transfusion requirements following elective coronary artery bypass grafting surgery. A prospective randomized trial is needed to confirm these findings.